CEO Mick Ruxin details the process of discovering which FDA approved drugs are best suited to combat cancer within patients.
March 15, 2023
January 18, 2023
January 16, 2023
May 25, 2022
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy . To find out more, read our Privacy Policy and our Cookie Policy.
